Skip to main content
Caplight Logo









Akribion Therapeutics

Akribion Therapeutics

Private
ZwingenbergHealthcare & Life Scienceshttps://akribion-therapeutics.com/

Last Round

Seed

Feb 4, 2025

Total Funding Raised

$8.32M

Company Overview

Akribion Therapeutics is a biotechnology company that develops a unique, RNA-guided, nuclease-based technology for programmable cell depletion.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

precision medicinegene silencingoncology therapeuticsGEiGSbiotech R&Dgene expression-based triggered gene silencingCRISPR-nucleasecancer therapyG-dase Eprogrammable medicinecell-type-specific therapytargeted cancer therapydrug discoverybiopharmanext-gen oncology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Akribion Therapeutics Comparables

Compare Akribion Therapeutics with similar companies based on industry and business-model similarity.

Akribion Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Shape Therapeutics
73%
Tune Therapeutics
71%
Arbor Biotechnologies
71%

Akribion Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedFeb 4, 2025

Key People

Founding team and executive leadership

Lukas Linnig

Founder Co-Chief Executive Officer

Founding Team

Michael Krohn

Co-Chief Executive Officer Co-Founder

Founding Team

Akribion Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 4, 2025

    BioTech startup emerges from stealth mode.

  • Feb 4, 2025

    $8.64M raised in Seed round.

Akribion Therapeutics Filings

Explore SEC and related filing metadata, where available.

Akribion Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Akribion Therapeutics's valuation, stock price, and market status.

Is Akribion Therapeutics a public or private company?

Akribion Therapeutics is a private company.

What is the current stock price of Akribion Therapeutics?

Akribion Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Akribion Therapeutics worth (valuation)?

Valuation information for Akribion Therapeutics is not publicly available.

Can I buy Akribion Therapeutics stock?

Akribion Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Akribion Therapeutics's last funding round?

Akribion Therapeutics's most recent funding round was Seed on February 4, 2025.

Who are the main investors in Akribion Therapeutics?

Key investors in Akribion Therapeutics include RV Invest, CARMA FUND.

Will Akribion Therapeutics IPO soon?

No public IPO plans have been announced for Akribion Therapeutics.

How can I track Akribion Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Akribion Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersZwingenberg
Employee Range13
Year Founded2024
Last FundingFeb 4, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?